Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Moderna readies interim analysis for its COVID-19 vaccine trial

By Brian Buntz | November 13, 2020

Moderna

Moderna Logo (PRNewsFoto/Moderna Therapeutics)

Pfizer (NYSE:PFE) and Moderna (NYSE:MRNA) are likely to be among the first companies to commercialize COVID-19 vaccines. But while the former has announced positive results from its interim analysis of its clinical study, the status of Moderna’s Phase 3 COVE trial remains a mystery.

The company announced that it remains blinded to whether the Phase 3 trial participants received its mRNA-1273 vaccine or placebo.

The company is preparing to share data from the trial with the independent Data Safety Monitoring Board overseeing the study.

Paving the way for the interim analysis is a “significant increase” in COVID-19 infections among trial participants. The trial required 53 people to become infected out of a pool of approximately 30,000. Given the recent rise in COVID-19 infections in the U.S., the interim analysis will likely have data from more than 53 patients infected with the virus.

While Pfizer’s delay in announcing its interim analysis fueled speculation, the company changed its interim analysis requirements from 32 to 64. As of November 8, at least 94 patients in its pool of 44,000 had contracted the novel coronavirus.

Anthony Fauci, the nation’s top infectious disease expert, has said that the Moderna trial results could be ready next week.

The Moderna vaccine, which must be held at –20° C, would require less-demanding storage requirements than Pfizer’s, which must be stored at –70° C.

The company has set a threshold for success of greater than 75% efficacy. Pfizer’s efficacy rate could be approximately 90%, based on its interim analysis.

Tell Us What You Think! Cancel reply

Related Articles Read More >

OncoSec eyes next steps with its cancer immunotherapy candidate
Norway investigating deaths of 23 individuals who received COVID-19 vaccine
Phastar
Phastar wins investment from Charterhouse Capital Partners
COVID-19 vaccine
Facial swelling and COVID-19 vaccines: 4 facts

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards